Overview

Pioglitazone and Serum Asymmetric Dimethylarginine (ADMA) in Patients With Diabetes

Status:
Completed

Trial end date:
2010-06-01

Target enrollment:

Participant gender:

Summary

SPECIFIC AIMS 1. To determine whether pioglitazone will reduce levels of asymmetric dimethylarginine(ADMA) in patients with diabetes. 2. To determine whether nitric oxide(NOx) products are increased with pioglitazone treatment. 3. To determine whether pioglitazone reduces oxidative stress (F2-isoprostanes).

Phase:

Phase 4

Details

Lead Sponsor:

Dana King
Medical University of South Carolina

Collaborator:

Takeda Pharmaceuticals North America, Inc.

Treatments:

N,N-dimethylarginine
Pioglitazone